These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35362393)

  • 1. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
    Tian Y; Lei Y; Fu Y; Sun H; Wang J; Xia F
    Curr Cancer Drug Targets; 2022; 22(6):454-462. PubMed ID: 35362393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
    Eun JW; Yoon JH; Ahn HR; Kim S; Kim YB; Lim SB; Park W; Kang TW; Baek GO; Yoon MG; Son JA; Weon JH; Kim SS; Cho HJ; Cheong JY
    Cancer Commun (Lond); 2023 Apr; 43(4):455-479. PubMed ID: 36919193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Takasu C; Miyazaki K; Shimada M
    PLoS One; 2021; 16(9):e0256755. PubMed ID: 34473785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
    Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
    BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms.
    Dahiya M; Dureja H
    J Chemother; 2022 Sep; 34(5):286-301. PubMed ID: 34291704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.
    Suzuki H; Iwamoto H; Seki T; Nakamura T; Masuda A; Sakaue T; Tanaka T; Imamura Y; Niizeki T; Nakano M; Shimose S; Shirono T; Noda Y; Kamachi N; Sakai M; Morita K; Nakayama M; Yoshizumi T; Kuromatsu R; Yano H; Cao Y; Koga H; Torimura T
    Cancer Commun (Lond); 2023 Apr; 43(4):415-434. PubMed ID: 36825684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
    EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
    Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
    Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
    Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
    Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
    de Rosamel L; Blanc JF
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
    Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW
    PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
    Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
    Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.